Health
Pfizer’s COVID vaccine shows ‘robust’ results in early trial – Medical Xpress
(HealthDay)—A vaccine based on cutting-edge RNA gene technology showed promising potency against the new coronavirus in an early trial, scientists report.
by E.j. Mundell, Healthday Reporter (HealthDay)A vaccine based on cutting-edge RNA gene technology showed promising potency against the new coronavirus in an early trial, scientists report.
The vaccine candidatefor now just called BNT162b1″elicited a robust immune response in participants, which increased with dose level and with a second dose,” according to a news release from the journal Nature, which published the trial data on Aug. 12.
The early phase 1/2 trial was led by Dr. Judith Absal…
Continue Reading